Review Article

Autologous Stem Cell Transplantation in Multiple Myeloma with Renal Failure: Friend or Foe?

Hongfei Zhong,1,2 Xiaojie Xie,3 and Gaosi Xu1

1Department of Nephrology, The Second Affiliated Hospital of Nanchang University, Jiangxi, China
2Grade 2015, The Second Clinical Medical College of Nanchang University, Jiangxi, China
3Department of Nephrology, 908 Hospital of People’s Liberation Army, Yingtan, China

Correspondence should be addressed to Gaosi Xu; gaosixu@163.com

Received 21 April 2019; Revised 22 September 2019; Accepted 30 September 2019; Published 29 October 2019

Academic Editor: Marc L. Turner

Copyright © 2019 Hongfei Zhong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Autologous stem cell transplantation (ASCT) is a standard treatment for multiple myeloma (MM), but the clinical response and renal curative effect in MM patients with renal failure (RF) remain controversial. The myeloma kidney disease has different types, and most are due to the direct toxic effects of light chain. Although ASCT can effectively clear the light chain, the data of renal function improvement are still limited. We reviewed the published literatures, focusing on the prospective studies, the retrospective analysis studies, and the case reports. RF patients who received ASCT displayed a low survival rate (OS: HR 1.95, 95% CI 1.020 to 3.720; \(I^2 = 64.9\%\), \(P = 0.014\)) and a shorter EFS/PFS (EFS/PFS: HR 1.53, 95% CI 1.090 to 2.140; \(I^2 = 0\%\), \(P = 0.014\)). However, ASCT was feasible and could have the similar clinical response outcomes compared with the normal renal function (CR: OR 1.013, 95% CI 0.569 to 1.804; \(I^2 = 48.5\%\), \(P = 0.101\); PR: OR 1.013, 95% CI 0.342 to 1.226; \(I^2 = 46.3\%\), \(P = 0.144\)). Moreover, MM with RF after ASCT had a good improvement of renal function and melphalan is still an important factor affecting the treatment of ASCT.

1. Introduction

Renal failure (RF) is one of the most common complications of multiple myeloma (MM), and it has been associated with higher risk of mortality and increased hospitalization rates due to complications such as electrolyte abnormalities, catheter-related complications, and infections [1, 2]. Factors contributing to myeloma kidney disease include hypercalcemia, dehydration, hyperuricemia, amyloid deposition and plasma cell infiltration, light chain-induced proximal tubular damage, cast nephropathy, and interstitial nephritis [3]. Furthermore, administration of nephrotoxic medication, dehydration, and hypercalcemia always adds to the development of acute kidney injury (AKI) [4–6]. Improved renal function is an important therapeutic aim and has become a predictor of better outcome in MM [7].

Autologous stem cell transplantation (ASCT) as a standard treatment for MM because of its association with longer event-free survival (EFS) and higher complete response (CR) rate [8, 9], it has been the mainstay of therapy in young patients (age < 65 years) with MM [10]. Historically, MM with RF appeared to have higher rates of transplant-related mortality (TRM) compared with the normal renal function (NRF) patients [11]. Although ASCT is still one of the disease’s most effective treatments [12], the presence of coexistent renal disease limits the therapeutic options and stem cell transplant eligibility [13]. In recent years, several reports have shown that the use of ASCT is safe and effective in MM with RF [14–18]. However, there still have some considerable variabilities in reported survival outcomes and renal recovery from the limited literature, and the studies included have different priorities in clinical and renal response.

Herein, we fully summarized the studies of ASCT in MM with RF, including the prospective studies, the retrospective studies, and the case reports. The diagnosis, types, and mechanisms of RF in MM are also discussed. More importantly, we analyzed the data of renal recovery and clinical response to answer the question of clinical controversy following ASCT treatment and evaluate whether MM with RF benefits from ASCT or not.
2. Diagnosis, Types, and Mechanisms of RF in MM

2.1. Diagnosis of RF in MM before the ASCT Therapy. The classification guidelines for renal failure in MM were adapted in 2014 [19]; eGFR was used only in patients with stable renal function. From the studies we included, most of them were according to the novel International Myeloma Working Group (IMWG) criteria for symptomatic MM [19], and it is based on either reduced creatinine clearance (CrCl < 40 ml/min) or elevated serum creatinine (SCr > 2 mg/dl). Although the criteria are more sensitive for the determination and evaluation of renal failure in nephropathy, the standards of RF in our included studies are still inconsistent; the diagnosis of renal failure in MM requires relatively uniform standards in the future.

2.2. Types of RF in MM. MM-associated RF can be classified into the following different types: cast nephropathy (CN), light chain (LC) amyloidosis (AL), Fanconi syndrome, and monoclonal immunoglobulin deposition disease (MIDD). CN accounts for 33%, MIDD 22%, and light chain amyloidosis 21% [2]. MIDD includes LC deposition disease (LCDD), predominant deposits of kappa LC, heavy-chain deposition disease, and light-heavy-chain deposition disease.

2.3. Mechanisms of RF in MM. Myeloma cast nephropathy is the major cause of renal failure in MM, which results from monoclonal LC precipitation with Tamm-Horsfall protein into casts that occlude the renal distal tubule lumens. Cast nephropathy develops when LC precipitation overcomes the capacity of tubular cells to catabolize and to endocytose the filtered free LCs [20, 21]. Moreover, nephrotoxic drugs (aminoglycoside antibiotics and nonsteroidal anti-inflammatory agents), hypercalcemia, dehydration, and contrast agents contribute to the development of renal failure [5, 22, 23]. As a result, the excess LCs form casts and aggregates with uromodulin in the distal nephron, leading to tubular obstruction and concomitant inflammation [20, 21, 24]. Furthermore, LC has direct toxic effects on kidney damage, and LC protein accumulates in renal tubular epithelial cells, inhibiting the metabolism of tubular cells and affecting the transportation of normal ions, amino acids, phosphates, etc. With the cast nephropathy developed, LCs can infiltrate the whole kidney and cause tubular, vascular, or glomerular damage. ASCT can effectively clear the LC, and renal damage may achieve remission; however, the data of renal function improvement are still limited.

3. ASCT in MM with RF: The Summarized Clinical Studies

There is growing concern about the curative effect of ASCT in MM with RF; more studies were reported to assess the clinical response and renal function in recent years. We fully summarized those studies but the included studies have different types, and the data of those studies were incomplete and variable. Therefore, we classified these studies into the cohort studies, the retrospective analysis studies, and the case reports, and the characteristics of each study are shown in Table 1. We fully summarized and classified the data of RF diagnosis, conditioning regimen, clinical response, survival, and response of renal function. Furthermore, we discovered that the present studies have different priorities in clinical and renal response; in the cohort studies, authors seemed to attach more weight to the clinical response. On the contrary, a retrospective analysis took more attention to renal function change. We also took a meta-analysis through the cohort study data to discuss whether the use of ASCT is safe and effective in MM with RF or not, and the data included the survival analysis, clinical response, and mortality.

3.1. ASCT in MM with RF: The Cohort Studies and Meta-Analysis

3.1.1. Search Strategy. We performed a literature search in February 2019 in the Elsevier, EMBASE, Web of Science, and PubMed databases.

The following search terms were used: (1) “Autologous stem cell transplantation” or “Monoclonal Gammapathies” or “ASCT”; (2) “renal failure” or “renal function” or “acute kidney injury”; (3) “multiple myeloma” or “myeloma” or “MM”; and (4) “the cohort studies,” “the retrospective analysis studies,” and “the case report studies.” In addition, the reference lists of retrieved papers and recent reviews were reviewed. The flow diagram of search strategy is presented in Figure 1.

3.1.2. Study Criteria. The inclusion criteria for studies were as follows: (1) the cohort studies comparing data on the clinical response and survival (“CR,” “PR,” “VGPR,” “OS,” “EFS,” “PFS,” and “TRM”); (2) validated diagnosis of renal failure and original research related to renal failure in MM patients; (3) studies that provided information about ASCT in MM with renal failure; and (4) articles that reported a clear comparison of RF (renal failure) population versus NRF (normal renal function) population controls with a direct effect on the clinical response and survival data.

The exclusion criteria were as follows: (1) duplicate studies; (2) studies such as systemic reviews, meta-analyses, and comments; and (3) studies of ASCT in MM with renal failure without detail research data in the clinical response and survival data.

3.1.3. Data Extraction. Data extracted from each study included the first author’s name, the publication year, the country of study origin, number of patients, median age, and the clinical response and survival (“CR,” “PR,” “VGPR,” “OS,” “EFS,” “PFS,” and “TRM”). If a study did not clearly mention any of the above key points, it had not performed the required methods. Two of the authors (Hongfei Zhong and Gaosi Xu) independently reviewed the selected studies and extracted data. Discrepancies were resolved by discussion.

3.1.4. Statistical Analysis. The data was abstracted and analyzed using Stata (version 12) to make the outcomes more comprehensive. The binary variable outcomes were the EFS/PFE and OS; the data were expressed as the hazard ratio (HR) with 95% CI (confidence interval), and the estimation...
| Author                  | Year | Country | Diagnosis of RF | Renal failure clinical stage in MM patient | Dialysis or not before ASCT | Therapy                  | Prognostic criteria |
|-------------------------|------|---------|----------------|------------------------------------------|----------------------------|--------------------------|-----------------------|
| ASCT in myeloma patients with renal insufficiency: the cohort studies |
| Antlanger et al. [29]   | 2018 | Austria | eGFR < 60 ml/min (MDRD) | ISS stage I (14%) II (30%) III (54%) | Not                        | Conventional chemotherapy + ASCT | eGFR (MDRD) |
| Gertz et al. [28]       | 2007 | USA     | SCr > 2 mg/dl | ISS stage I (0%) II (20%) III (80%) | Not                        | Conditioning regimen (Mel) + ASCT | NR |
| Knudsen et al. [16]     | 2015 | Denmark | CrCl < 60 ml/min | ISS stage II (8%) III (21%) | Not                        | Conditioning regimen (Mel) + ASCT | NR |
| Mahindra et al. [27]    | 2017 | USA     | eGFR < 30 ml/min (MDRD) | Severe RF | Not                        | Conditioning regimen (Mel) + ASCT | NR |
| Raab et al. [25]        | 2006 | USA     | SCr > 2 mg/dl | ISS stage I (14%) II (10%) III (74%) | Not                        | Conditioning regimen (Mel) + ASCT | NR |
| San Miguel et al. [26]  | 2000 | Spanish | SCr > 2 mg/dl | ISS stage II (14%) III (86%) | Not                        | Conditioning regimen (Mel) + ASCT | CrCl |
| ASCT in myeloma patients with renal insufficiency: the retrospective analysis studies |
| Badros et al. [32]      | 2001 | USA     | Creatinine > 176.8 μmol/l | NR | Not                        | Conditioning regimen (Mel) + ASCT | NR |
| Augeul-Meunier et al. [30] | 2018 | France   | CrCl < 30 ml/min | NR | Dialysis dependence (47%) | Conditioning regimen (Mel) + ASCT | NR |
| Ballester et al. [34]   | 1997 | USA     | SCr > 3 mg/dl | NR | Dialysis dependence (67%) | BUCY + ASCT | SCr |
| Balsam et al. [35]      | 2017 | USA     | GFR | CKD stage Stage 1 (31.8%) Stage 2 (43.8%) Stage 3 (17.7%) Stage 4 (3.1%) Stage 5 (1.6%) | Not                        | Conventional chemotherapy + ASCT | GFR |
| Bernard et al. [18]     | 2015 | Canada  | NR | ISS stage I (14%) II (10%) III (74%) | Dialysis dependence (53%) | Conditioning regimen (Mel) + ASCT | CrCl |
| Glavey et al. [36]      | 2011 | USA     | SCr > 3 mg/dl | CKD stage IIIa (78%) IIIb (12%) | Not                        | Conditioning regimen (Mel) + ASCT | eGFR (MDRD) |
| Seok Hui et al. [47]    | 2011 | Korea   | eGFR (MDRD) | CKD stage IIIb (100%) | Not                        | Conditioning regimen (Mel) + ASCT | eGFR (MDRD) |
| Parikh et al. [33]      | 2009 | USA     | SCr > 2 mg/dl | Dialysis dependence (20%) | Not                        | Conditioning regimen (Mel) + ASCT | eGFR (MDRD) |
| Tosi et al. [31]        | 2000 | Italy   | CrCl < 40 ml/h | CKD stage IIIb (100%) | Not                        | Conventional chemotherapy + ASCT | CrCl |
Table 1: Continued.

| Author          | Year | Country | Diagnosis of RF | Renal failure clinical stage in MM patient | Dialysis or not before ASCT | Therapy Prognostic criteria |
|-----------------|------|---------|-----------------|----------------------------------------|-----------------------------|-----------------------------|
| Bigé et al. [39]| 2009 | France  | SCr             | Acute renal failure                     | Not                         | Conditioning regimen (Mel)+ASCT SCr |
| Lam et al. [38] | 2004 | China   | Normal renal function | Normal renal function | Not          | ASCT                        | NR                          |
| Rebibou et al. [40] | 1997 | France  | NR              | Severe renal failure                    | Not                         | Conditioning regimen (Mel)+ASCT NR |
| Reiter et al. [37] | 1999 | Austria | NR              | NR                                      | Not                         | Conditioning regimen (VAD)+ASCT CrCl |
| Tauro et al. [41] | 2002 | UK      | NR              | NR                                      | Not                         | Conditioning regimen (Mel)+ASCT SCr |

ASCT: autologous stem cell transplantation; RF: renal failure; CrCl: creatinine clearance; SCr: serum creatinine; NR: not reported; MDRD: Modification of Diet in Renal Disease; eGFR: estimated glomerular filtration rate; ISS: international staging system; CKD: chronic kidney diseases; BUCY: Busulfan and Toxicity cyclophosphamide; Mel: melphalan; GFR: glomerular filtration rate; VAD: dexamethasone.

Records identified through database searching (n = 263)
PubMed = 34
Elsevier = 35
Embase = 68
Web of science = 126

Duplicates (n = 36)

Records screened (n = 227)
(i) Off topic (n = 165)
(ii) Not cohort or retrospective analysis studies or case report (n = 38)
(iii) System review or meta-analysis (n = 4)

Studies included in qualitative synthesis (n = 20)

The retrospective analysis studies (n = 9)
The cohort studies (n = 6)
The case report studies (n = 5)

Studies included in qualitative synthesis (meta-analysis) (n = 6)

Figure 1: Flow diagram representing the selection process.
of the effect was performed by using a random effects model. Other binary variable outcomes were the PR and CR, and the date were expressed as the odds ratio (OR) with 95% CI (confidence interval); when combining studies, the random effects model was used to account for study heterogeneity. We used Q statistic and I² tests to evaluate the heterogeneity. Low, moderate, and high heterogeneities were represented by thresholds of<25%, 25-75%, and >75%, respectively. P ≤ 0.05 was considered significant in all statistical tests.

3.1.5. Data Analysis. Recently, some studies reported the safety and clinical efficacy of ASCT use in myeloma patients with RF (Table 2) [16, 25–29]. Six articles [16, 25–29] with a total of 2930 MM patients were included in the meta-analysis. The binary variable outcomes were the incidence of overall survival (OS), event-free survival (EFS), progression-free survival (PFS), complete response (CR), partial response (PR), very good partial response (VGPR), and transplantation-related mortality (TRM). In addition, the data of OS and EFS expressed as the hazard ratio (HR) with 95% confidence interval (CI), and the data of CR, PR, VGPR, and TRM were expressed as the odds ratio (OR) with 95% CI; the estimation of the effect of the was performed by using a random effects model. The clinical response and survival analysis in MM with RF after ASCT are shown in Figure 2. To the best of our knowledge, this is the only and the first meta-analysis that reported the clinical response and survival data of ASCT treatment in MM with RF. Obviously, the results showed that the use of ASCT was associated with increased risk of mortality, and the outcome was consistent with the previous studies [13]. The CR (OR 1.013, 95% CI 0.569 to 1.804; I² = 48.5%, P = 0.101) and PR (OR 1.013, 95% CI 0.342 to 1.226; I² = 46.3%, P = 0.144) were not significantly different between the RF and NRF groups. Survival analysis indicated that MM with RF have lower survival rates (OS: HR 1.95, 95% CI 1.020 to 3.720; I² = 64.9%, P = 0.014), and the major cause of a low survival rate in MM with RF may be due to the high toxicity in ASCT therapy. As a whole, ASCT was feasible and could lead to similar clinical response outcomes compared with those without advanced renal failure, but the survival analysis seemed to be not optimistic. Moreover, we noticed that the number of patients in some studies was relatively small. So large-size cohort studies are needed to prove this conclusion of ASCT for MM with RF in the future. Unfortunately, these reports had limit outcomes of renal response; only three studies [16, 26, 29] reported the renal function change.

3.2. ASCT in MM with RF: The Retrospective Analysis Studies. Nine retrospective analysis studies reported the outcome of ASCT treatment in MM with RF, these studies were done to mainly observe the alteration of the RF in MM patients. It was revealed that few studies focus on the clinical response and survival data and most retrospective studies tend to observe the renal response, and it was contrary to the emphasis of previous cohort studies [16, 25–29]. In general, fewer clinical response (CR, PR, and VGPR) was reported in the retrospective analysis studies. From the existing data, ASCT treatment seemed to have a better PR rate (62%), and the CR was 38% (Table 3). Augeul-Meunier et al. and Tosi et al. reported a good PR (96%, 67%); these studies mostly used low doses of melphalan [30, 31]. Badros et al. and Bernard et al. reported a good CR (50%, 43%), but the dose of melphalan was high [18, 32]. We indicated that the dose of melphalan escalation may result in higher response rates. Overall, from the retrospective studies, we conclude that ASCT as a good clinical response treatment could be an effective therapy in MM with RF.

Although cohort studies [16, 25–29] reported the clinical efficacy of ASCT use in MM with RF, however, the data of renal function response was less. We summarized the retrospective analysis studies that reported renal function response, and these studies complemented the renal response outcome of the previous cohort studies. Parikh et al. [33], Bernard et al. [18], Augeul-Meunier et al. [30], Ballester et al. [34], Balsam et al. [35], Glavey et al. [36], and Tosi et al. [31] reported the renal response after ASCT, and the improvements in renal function were 32%, 25%, 60%, 17%, 33%, 100%, and 83%, respectively. However, the definition of RF in each study was different. From the limited research, we found that lower-dose melphalan might have a better improvement of renal function (Augeul-Meunier et al. 60%, Glavey et al. 100%, and Tosi et al. 83%, respectively). On the contrary, the improvements of patients with renal recovery in the high-dose melphalan group were 32% and 25%. What is more, the USA Myeloma Group reported that the patients with RF underwent ASCT and ten patients (21%) experienced downstaging of renal failure [33]. It also reminds us that high doses of melphalan are associated with severe renal failure and should be used cautiously. On the other hand, age may also be an important factor affecting the curative effect of ASCT treatment. Tosi et al. [31, 37] reported a good renal function improvement, and the median ages were 49 and 47. A previous study also indicated that ASCT has been the mainstay of therapy in young patients with MM [10]. ASCT treatment may have age limitations, especially in patients with RF. However, some researches associated with older patients still have a safe and efficacy treatment of renal recovery [30, 36]; controversies exist about the benefits of transplantation for patients with older age. A future study needs to assess the effects of age values at the time of ASCT treatment in MM. Furthermore, patients in four retrospective analysis studies suffered a predialysis before ASCT [30, 33, 34, 36]. It appears from the data at hand that there is almost no connection between the predialysis and the outcome of ASCT therapy.

3.3. ASCT in MM with RF: The Case Report Studies. Five case report studies [37–41] were included in our research, and our summary is shown in Table 4. One patient reported an acute renal tubular necrosis, which may due to the consumption of cooked grass carp fish in the night. In contrast to those of other patients in the four studies, the renal functions were improved.

Two studies (Bigé et al. and Tauro et al.) have shown a renal improved advantage for patients who receive ASCT with a high-dose melphalan (200 mg/m²) treatment; this is in contrast to our retrospective study data. Historically,
Table 2: ASCT in myeloma patients with renal failure, the cohort studies.

| Author                  | Country | No.  | Median age | Diagnosis of RF | Conditioning regimen | NRF/RF | Clinical response and survival (NRF/RF) (%) | Response of renal function in RF group |
|-------------------------|---------|------|------------|-----------------|----------------------|--------|---------------------------------------------|-----------------------------------------|
| Antlanger et al. [29]   | Austria | 288  | 57         | eGFR < 60 ml/min (MDRD) | Conventional chemotherapy | 238/50 | 41/36 26/17 28/28 70/68 NR 29/27 NR | Creatinine 2.6 mg/ml decreased to 2.0 mg/ml and eGFR 33 increased to 41 ml/min/1.73 m² |
| Gertz et al. [28]       | USA     | 677  | 59         | SCr > 2 mg/dl    | Melphalan (140/200 mg/m²) | 637/40 | NR NR NR 48/24 NR NR NR NR NR | NR                                      |
| Knudsen et al. [16]     | Denmark | 107  | 56         | 9                | Melphalan (100/140/200 mg/m²) | 78/29 | 93/83 93/83 NR 85/52 50/27 NR 1/17 | 10 patients reached a normal renal function |
| Mahindra et al. [27]    | USA     | 1307 | 60         | eGFR < 30 ml/min (MDRD) | Melphalan (140/200 mg/m²) | 1240/67 | 32/34 23/24 30/16 70/60 NR 35/27 25/33 | NR                                      |
| Raab et al. [25]        | USA     | 34   | 58         | SCr > 2 mg/dl    | Melphalan (100/200 mg/m²) | 17/17 | 53/59 24/24 NR 70/42 20/18 NR 6/6 | NR                                      |
| San Miguel et al. [26]  | Spanish | 493  | 55         | SCr > 2 mg/dl    | Melphalan (140 mg/m²) | 479/14 | 48/80 43/10 NR 61/56 NR 44/27 3.3/29 | 6 patients reached levels of creatinine 2 mg/dl and CrCl 50 ml/min |

ASCT: autologous stem cell transplantation; RF: renal failure; CrCl: creatinine clearance; SCr: serum creatinine; OS: overall survival; EFS: event-free survival; PFS: progression free survival; CR: complete response; PR: partial response; VGPR: very good partial response; TRM: transplantation related mortality; NR: not reported; MDRD: Modification of Diet in Renal Disease; eGFR: estimated glomerular filtration rate.
patients with RF either have received reduced doses or have been excluded from ASCT therapy with high-dose melphalan. Perhaps, the researchers prefer to report that high-dose melphalan has encountered dose-limiting toxicities, especially in MM with RF. Furthermore, low doses of melphalan use may result in higher response rates. We also found that the dose of melphalan use may be the source of heterogeneity in the meta-analysis. Owing to the limited data of dose gradient of melphalan, the data of survival analysis was indicated that low-dose melphalan (melphalan 80 and 140 mg/m²) treatment might have a lower mortality [30, 32], but with the increase of melphalan doses, the TRM was increased [18]. Furthermore, low doses of melphalan use may achieve a good PR [30, 31], and high doses might have a good benefit in CR [18, 32]; the dose of melphalan escalation may result in higher response rates. We also found low-dose melphalan (melphalan 80 mg/m², 140 mg/m²) treatment might have a lower mortality [30, 32], but with increasing doses of melphalan, the data of survival analysis was controversial. As for the renal improvement aspect, low-

**4. Melphalan: Is It Safe for MM with RF?**

Melphalan is probably the most effective chemotherapeutic agent in MM with a clear dose-response effect, and melphalan usually is a conditioning regimen before ASCT treatment. It has shown reduced overall mortality and improved PFS compared to conventional chemotherapy in MM [8, 9, 41, 42]. The standard conditioning regimen of melphalan (a dose of 200 mg/m²) was used for patients with NRF [43], melphalan has a dose-response antitymoma effect, and higher doses could potentially improve the clinical response when used as a conditioning regimen for ASCT [44]. Unfortunately, melphalan has encountered dose-limiting toxicities, especially in MM with RF. Because of conflicting data on altered melphalan pharmacokinetics in renal insufficiency, patients with creatinine levels >2 mg/dl have usually been excluded from high-dose melphalan treatment [45, 46]. However, some studies have found high-dose chemotherapy with melphalan can be administered to selected patients with RF [34, 40]. Our two case reports also come to the same conclusion [39, 41], and RF might no longer constitute a criterion for dose reduction or exclusion from such therapy.

In our summarized clinical studies, the data associated with melphalan dose were chaotic, and most studies showed that the dose of melphalan use was arbitrary (from 100 to 200 mg/m²), and the definition of high-dose melphalan was different in each study [30, 33]. In the cohort study groups, five researchers reported the use of melphalan as the conditioning regimen during the ASCT treatment [16, 25–28]; the dose of melphalan use may be the source of heterogeneity in the meta-analysis. Owing to the limited data of dose gradient of melphalan use, we cannot take a subgroup to assess whether the dose gradient of melphalan will affect the survival analysis of ASCT treatment in MM with RF. However, existing data concluded that remission rate may not be affected by the melphalan use (CR: OR 1.013, 95% CI 0.569 to 1.80; I² = 48.5%, P = 0.101; PR: OR 1.013, 95% CI 0.342 to 3.24; I² = 64.3%, P = 0.144), and the heterogeneity of data was acceptable. In the retrospective analysis studies, six studies used melphalan as the conditioning regimen, and we indicated that low-dose melphalan (melphalan 80 mg/m², 140 mg/m²) treatment might have a lower mortality [30, 32], but with the increase of melphalan doses, the TRM was increased [18]. Furthermore, low doses of melphalan use may achieve a good PR [30, 31], and high doses might have a good benefit in CR [18, 32]; the dose of melphalan escalation may result in higher response rates. We also found low-dose melphalan (melphalan 80 and 140 mg/m²) treatment might have a lower mortality [30, 32], but with increasing doses of melphalan, the data of survival analysis was controversial. As for the renal improvement aspect, low-
| Author               | Country | No. | Median age | Diagnosis of RF          | Conditioning regimen | Clinical response and survival (%) | Response of renal function in the RF group |
|----------------------|---------|-----|------------|--------------------------|----------------------|----------------------------------|------------------------------------------|
| Badros et al. [32]   | USA     | 81  | 53         | Creatinine > 176.8 μmol/l| Mel140 (26%) Mel200 (74%) | 58 NR NR 55 48 6 | 10 patients (18%) presented minor renal response and 1 with partial renal response |
| Augeul-Meunier et al. [30] | France   | 55  | 61         | CrCl < 30 ml/min         | Mel140 (87%) Mel200 (13%) | 43 96 58 72 NR 45 6 | Proteinuria decreased for the majority of patients (60%) |
| Ballester et al. [34] | USA      | 6   | 50         | SCr > 3 mg/dl            | BU CY               | 17 50 NR 50 NR NR 50 | 1 patient (17%) has shown a progressive recovery of renal function (SCr was decreased) |
| Balsam et al. [35]   | USA     | 192 | 57.1       | GFR                      | Conventional chemotherapy Mel 140 (36%) Mel 200 (61%) | NR NR NR NR NR NR NR NR | 64 patients (33%) reversed renal failure (GFR was increased) |
| Bernard et al. [18]  | Canada  | 33  | 56         | NR                       | Mel 160 (3%) Mel 200 (61%) | 50 46 50 63 NR NR 15 | 7 patients (25%) had an improved renal function |
| Glavey et al. [36]   | USA     | 30  | 61         | SCr > 3 mg/dl            | NR NR NR NR NR NR NR NR | Average creatinine 4.9 mg/dl decreased to 3.9 mg/dl |
| Seuk Hui et al. [47] | Korea    | 41  | 49         | eGFR (MDRD)              | Mel 100 (100%) | NR NR NR NR NR NR NR NR | Average eGFR decreased in 24 months |
| Parikh et al. [33]   | USA     | 46  | 56         | SCr > 2 mg/dl            | Mel 140 (6%) Mel 180 (29%) Mel 200 (65%) | 22 53 NR 64 NR 36 NR | 15 patients (32%) experienced a sustained improvement in renal function (eGFR was increased) |
| Tosi et al. [31]     | Italy   | 6   | 47         | CrCl < 40 ml/l           | Mel 80 (83%) | 0 67 0 NR NR NR | 10 patients (21%) experienced a downstaging of renal failure |

ASCT: autologous stem cell transplantation; BU CY: Busulfan and Toxicity cyclophosphamide; RF: renal failure; Mel: melphalan; CrCl: creatinine clearance; SCr: serum creatinine; GFR: glomerular filtration rate; eGFR: estimated glomerular filtration rate; OS: overall survival; EFS: event-free survival; PFS: progression free survival; CR: complete response; PR: partial response; VGPR: very good partial response; TRM: transplantation related mortality; NR: not reported; MDRD: Modification of Diet in Renal Disease.
| Author            | Year | Country | Age | Immunochemical subtype | Renal function before ASCT | Treatment                                                                 | Clinical response and renal function after ASCT |
|-------------------|------|---------|-----|-------------------------|-----------------------------|---------------------------------------------------------------------------|-----------------------------------------------|
| Bigé et al. [39]  | 2009 | France  | 57/56 | Case 1: light chain     | Case 1: acute renal failure, Scr 673 μmol/l | Case 1: ASCT was performed after high-dose melphalan (200 mg/m²) | Case 1: Scr 673 μmol/l decreased to 280 μmol/l |
|                   |      |         |      | Case 2: IgA              | Case 2: acute renal failure, Scr 576 μmol/l | Case 2: treated with five courses of VAD chemotherapy and then received ASCT | Case 2: Scr 576 μmol/l decreased to 450 μmol/l |
|                   |      |         |      |                         |                             | Received a non-myeloablative ASCT                                         |                                               |
| Lam et al. [38]   | 2004 | China   | 63  | IgA                     | Normal renal function       | Acute renal tubular necrosis                                              |                                               |
| Rebibou et al. [40]| 1997 | France  | 49  | IgG                     | Severe renal failure        | The therapeutic regimen consisting of one high-dose melphalan infusion and ASCT was infused 5 days after melphalan | CR: 14 months                                 |
| Reiter et al. [37]| 1999 | Austria | 51  | Light chain             | Scr 1.9 mg/dl               | CrCl had improved to 46 ml/min                                             |                                               |
| Tauro et al. [41] | 2002 | UK      | 52  | NR                      | Scr 690 μmol/l              | The patient was treated with high-dose melphalan (200 mg/m³); then ASCT was infused | SCR 690 μmol/l decreased to 429 μmol/l        |

ASCT: autologous stem cell transplantation; MM: multiple myeloma; SCr: serum creatinine; CrCl: creatinine clearance; CR: complete response; VAD: vincristine, adriamycin, and dexamethasone; NR: not reported.
dose melphalan use has demonstrated a good renal recovery from the retrospective studies. However, with the process of the increased dose, changes in renal function have been described in different outcomes, so clinical trials are required for more evaluation of high-dose melphalan use in MM with RF, especially in renal recovery outcomes.

5. Conclusion

Accumulating evidence suggests that in MM with RF, ASCT could be a feasible therapy and can lead to similar remission outcomes to those without advanced RF. Our current study indicated that the MM with RF after ASCT truly has a good improvement of renal function but has a low survival rate. For the recovery of kidney function in MM patients, ASCT may probably be a friend, but it may be a foe due to the low survival rate. In general, from the overall efficacy, ASCT is worth a try in MM patients with RF. The clinical response of the conditioning melphalan therapy in RF patients remains controversial, especially in dose response of melphalan use. Moreover, melphalan is still an important factor affecting the treatment of ASCT.

Abbreviations

RF: Renal failure
MM: Multiple myeloma
ASCT: Autologous stem cell transplantation
NRF: Normal renal function
AKI: Acute kidney injury
LC: Light chain
MIDD: Monoclonal immunoglobulin deposition disease
LCDD: LC deposition disease
CN: Cast nephropathy
IL: Interleukin
HR: Hazard ratio
OR: Odds ratio
RIFLE: Risk, Injury, Failure, Loss and End-Stage Kidney Disease
AKIN: Acute Kidney Injury Network
IMWG: International Myeloma Working Group
MDRD: Modification of Diet in Renal Disease
CrCl: Creatinine clearance
SCr: Serum creatinine
OS: Overall survival
EFS: Event-free survival
PFS: Progression-free survival
CR: Complete response
PR: Partial response
VGPR: Very good partial response
TRM: Transplantation-related mortality.

Additional Points

**Highlights.** (i) The studies of ASCT in MM with RF were fully summarized. (ii) The diagnosis, types, and mechanisms of RF in MM were discussed. (iii) The data of renal recovery and clinical response during ASCT treatment were analyzed. (iv) Whether MM with RF benefits from ASCT or not was evaluated. (v) Melphalan is still an important factor affecting the treatment of ASCT.

Conflicts of Interest

No any conflict of interest was reported in this work.

Authors’ Contributions

Hongfei Zhong and Xiaojie Xie contributed equally to this work.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (No. 81970583), the Supporting Project for the Foreigers of Main Disciplines of Jiangxi Province (No. 20162BCB22023), the “5511” Innovative Drivers for Talent Teams of Jiangxi Province (No. 20165BCB18018), and the Natural Science Foundation of Jiangxi Province (No. 20181BAB205016).

References

[1] C. C. Chow, K. L. Mo, C. K. Chan, H. K. Lo, K. S. Wong, and J. C. W. Chan, “Renal impairment in patients with multiple myeloma,” *Hong Kong Medical Journal*, vol. 9, no. 2, pp. 78–82, 2003.
[2] E. C. Heher, H. G. Rennke, J. P. Laubach, and P. G. Richardson, “Kidney disease and multiple myeloma,” *Clinical Journal of the American Society of Nephrology*, vol. 8, no. 11, pp. 2007–2017, 2013.
[3] M. A. Dimopoulos, P. Sonneveld, N. Leung et al., “International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment,” *Journal of Clinical Oncology*, vol. 34, no. 13, pp. 1544–1557, 2016.
[4] R. A. Kyle, M. A. Gertz, T. E. Witzig et al., “Review of 1027 patients with newly diagnosed multiple myeloma,” *Mayo Clinic Proceedings*, vol. 78, no. 1, pp. 21–33, 2003.
[5] M. A. Dimopoulos, E. Kastritis, L. Rosinol, J. Bladé, and H. Ludwig, “Pathogenesis and treatment of renal failure in multiple myeloma,” *Leukemia*, vol. 22, no. 8, pp. 1485–1493, 2008.
[6] V. Eleutherakis-Papaikakou, A. Bamias, D. Gika et al., “Renal failure in multiple myeloma: incidence, correlations, and prognostic significance,” *Leukemia & Lymphoma*, vol. 48, pp. 337–341, 2006.
[7] D. Fotiou, M. A. Dimopoulos, and E. Kastritis, “Managing renal complications in multiple myeloma,” *Expert Review of Hematology*, vol. 9, no. 9, p. 1, 2016.
[8] M. Attal, J. L. Harousseau, A. M. Stoppa et al., “A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma,” *The New England Journal of Medicine*, vol. 335, no. 2, pp. 91–97, 1996.
[9] M. Hussein, “Role of high-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma,” *Leukemia*, vol. 18, no. 4, p. 893, 2004.
[10] S. Mahajan, N. Tandon, and S. Kumar, “The evolution of stem-cell transplantation in multiple myeloma,” *Therapeutic Advances in Hematology*, vol. 9, no. 5, pp. 123–133, 2018.
[11] H. Jean-Luc and M. Philippe, “Autologous hematopoietic stem-cell transplantation for multiple myeloma,” The New England Journal of Medicine, vol. 360, no. 25, pp. 2645–2654, 2013.

[12] E. C. Heher and T. R. Spitzer, “Hematopoietic stem cell transplantation in patients with chronic kidney disease,” Seminars in Nephrology, vol. 30, no. 6, pp. 602–614, 2010.

[13] B. M. Augustsson, B. Gulnaz, J. A. Dunn et al., “Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party,” Journal of Clinical Oncology, vol. 23, no. 36, pp. 9219–9226, 2005.

[14] M. A. Dimopoulos, M. Roussou, M. Gavriatopoulou et al., “Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis,” American Journal of Hematology, vol. 91, no. 5, pp. 499–502, 2016.

[15] M. A. Dimopoulos, M. Roussou, M. Gkotzamanidou et al., “The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma,” Leukemia, vol. 27, no. 2, pp. 423–429, 2013.

[16] L. M. Knudsen, B. Nielsen, P. Gimsing, and C. Geisler, “Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure,” European Journal of Haematology, vol. 75, no. 1, pp. 27–33, 2015.

[17] C.-K. Lee, M. Zangari, B. Barlogie et al., “Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant,” Bone Marrow Transplantation, vol. 33, p. 823, 2004.

[18] R. St Bernard, L. Chodirker, E. Masih-Khan et al., “Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure,” Bone Marrow Transplantation, vol. 50, no. 1, pp. 95–99, 2015.

[19] S. V. Rajkumar, M. A. Dimopoulos, A. Palumbo et al., “International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma,” The Lancet Oncology, vol. 15, no. 12, pp. e538–e548, 2014.

[20] K. Efstathios, T. Evangelos, and M. A. Dimopoulos, “Current treatments for renal failure due to multiple myeloma,” Expert Opinion on Pharmacotherapy, vol. 14, no. 11, pp. 1477–1495, 2013.

[21] S. Sule, Z. Craig, E. E. Simon, K. Aditi, P. C. Singhal, and B. Vecchi, “Endocytosis of light chains induces cytokines through activation of NF-xB in human proximal tubule cells,” Kidney International, vol. 62, no. 6, pp. 1977–1988, 2002.

[22] C. A. Hutchison, V. Batuman, J. Behrens et al., “The pathogenesis and diagnosis of acute kidney injury in multiple myeloma,” Nature Reviews Nephrology, vol. 8, pp. 43–51, 2011.

[23] A. M. From, B. J. Bartholmai, A. W. Williams, S. S. Cha, P. Axel, and F. S. McDonald, “Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: a retrospective cohort study of 7977 patients at mayo clinic,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 1, pp. 10–18, 2008.

[24] Z. Q. Huang and P. W. Sanders, “Biochemical interaction between Tamm-Horsfall glycoprotein and Ig light chains in the pathogenesis of cast nephropathy,” Laboratory Investigation, vol. 73, p. 810, 1995.

[25] M. S. Raab, I. Breitkreutz, M. Hundemer et al., “The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure,” Haematologica, vol. 91, p. 1555, 2006.

[26] J. F. San Miguel, J. L. Lahuerta, R. Garcia-Sanz et al., “Are myeloma patients with renal failure candidates for autologous stem cell transplantation?”, The Hematology Journal, vol. 1, no. 1, pp. 28–36, 2000.

[27] A. Mahindra, P. Hari, R. Fraser et al., “Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis,” Bone Marrow Transplantation, vol. 52, no. 12, pp. 1616–1622, 2017.

[28] M. A. Gertz, M. Q. Lacy, A. Dispensieri et al., “Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma,” Bone Marrow Transplantation, vol. 39, no. 10, pp. 605–611, 2007.

[29] M. Antlanger, T. Dust, T. Reiter et al., “Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study,” BMC Cancer, vol. 18, no. 1, article 1008, 2018.

[30] K. Augeul-Meunier, M. L. Chretien, A. M. Stoppa et al., “Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC,” Bone Marrow Transplantation, vol. 53, no. 6, pp. 749–755, 2018.

[31] P. Tosi, E. Zamagni, S. Ronconi et al., “Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure,” Leukemia, vol. 14, no. 7, pp. 1310–1313, 2000.

[32] A. Badros, B. Barlogie, E. Siegel et al., “Results of autologous stem cell transplant in multiple myeloma patients with renal failure,” British Journal of Haematology, vol. 114, no. 4, pp. 822–829, 2001.

[33] G. C. Parikh, A. Ali Imran, R. M. Saliba et al., “Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma,” Biology of Blood and Marrow Transplantation, vol. 15, no. 7, pp. 812–816, 2009.

[34] O. F. Ballester, R. Tummala, W. E. Janssen et al., “High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency,” Bone Marrow Transplantation, vol. 20, no. 8, p. 653, 1997.

[35] L. Balsam, C. Saad, C. Arsene, and J. Fogel, “Impact of autologous stem cell transplantation on blood pressure and renal function in multiple myeloma patients,” Journal of the National Medical Association, vol. 109, no. 3, pp. 182–191, 2017.

[36] S. V. Glavey, M. A. Gertz, A. Dispensieri et al., “100 long term outcome of renal failure in multiple myeloma following autologous stem cell transplant,” American Journal of Kidney Diseases, vol. 57, no. 4, pp. B41–B41, 2011.

[37] E. Reiter, P. Kalhs, F. Keil et al., “Effect of high-dose melphalan and peripheral blood stem cell transplantation on renal function in patients with multiple myeloma and renal insufficiency: a case report and review of the literature,” Annals of Hematology, vol. 78, no. 4, pp. 189–191, 1999.

[38] M. F. Lam, K. C. Tse, K. W. Chan, and W. Y. Au, “Acute renal tubular necrosis due to grass carp ingestion in a myeloma patient after allogeneic stem cell transplantation,” Bone Marrow Transplantation, vol. 33, no. 6, pp. 669–670, 2004.
[39] N. Bigé, B. Guéry, R. Delarue, L. Noël, and F. Fakhouri, “Late recovery of renal failure after autologous haematopoietic stem cell transplantation for multiple myeloma: a report of two cases,” *Clinical Kidney Journal*, vol. 2, no. 3, pp. 242–245, 2009.

[40] J. M. Rebibou, D. Caillot, R. O. Casasnovas et al., "Peripheral blood stem cell transplantation in a multiple myeloma patient with end-stage renal failure," *Bone Marrow Transplantation*, vol. 20, no. 1, pp. 63–65, 1997.

[41] S. Tauro, F. J. Clark, N. Duncan, G. Lipkin, N. Richards, and P. Mahendra, “Recovery of renal function after autologous stem cell transplantation in myeloma patients with end-stage renal failure,” *Bone Marrow Transplantation*, vol. 30, no. 7, pp. 471–473, 2002.

[42] F. Jean-Paul, K. Sandrine, D. Marine et al., "High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the group Myelome-Autogreffe," *Journal of Clinical Oncology*, vol. 23, no. 36, pp. 9227–9233, 2005.

[43] J. Blade, L. Rosinol, M. T. Cibeira, M. Rovira, and E. Carreras, “Hematopoietic stem cell transplantation for multiple myeloma beyond 2010,” *Blood*, vol. 115, no. 18, pp. 3655–3663, 2010.

[44] P. Moreau, T. Facon, M. Attal et al., "Comparison of 200 mg/m² melphalan and 8 Gy total body irradiation plus 140 mg/m² melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial," *Blood*, vol. 99, no. 3, pp. 731–735, 2002.

[45] J. L. Harousseau, N. Milpied, J. P. Laporte et al., "Double-intensive therapy in high-risk multiple myeloma,” *Blood*, vol. 79, pp. 2827–2833, 1992.

[46] D. Cunningham, L. Paz-Ares, S. Milan et al., "High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma," *Journal of Clinical Oncology*, vol. 12, no. 4, pp. 759–763, 1994.

[47] K. Seok Hui, H. Hyeon Seok, P. Hoon Suk et al., "Changes in renal function after different tandem hematopoietic stem-cell transplantation approaches in patients with multiple myeloma," *Journal of Korean Medical Science*, vol. 26, no. 10, article 1310, 2011.